What does the changing drug discovery and development landscape mean for the future?
Manage episode 344774994 series 1919400
This is the latest episode of the free DDW podcast, which covers three articles written for Volume 22, Issue 4 – Fall 2021 of DDW, narrated by DDW Multimedia Editor Megan Thomas.
They are called “The potential of small molecules and biologics for new therapeutics”, “AE reporting turnarounds and the translation issue” and “Why we are on the cusp of a golden age of medicine”.
Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. In the first article, he talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.
In the second article, Kathleen O’Brien of Amplexor Life Sciences lays out a blueprint for centralising global AE reporting.
In the third article, Panna Sharma, the President and CEO of Lantern Pharma, a clinical-stage oncology biotech using AI and genomics to innovate the rescue, revitalisation, and development of precision cancer therapeutics, spoke to Lu Rahman about this biotech and explains why he believes AI is about to change the drug development landscape.